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ABSTRACT
Axial spondyloarthritis (axSpA) is a chronic rheumatic 
disease characterised by inflammation predominantly 
involving the spine and the sacroiliac joints. In some 
patients, axial inflammation leads to irreversible structural 
damage that in the spine is usually quantified by the 
modified Stoke Ankylosing Spondylitis Spinal Score 
(mSASSS). Available therapeutic options include biological 
disease- modifying antirheumatic drugs (bDMARDs), which 
have been proven effective in suppressing inflammation 
in several randomised controlled trials (RCT), the gold 
standard for evaluating causal treatment effects. RCTs 
are, however, unfeasible for testing structural effects in 
axSpA mainly due to the low sensitivity to change of the 
mSASSS. The available literature therefore mainly includes 
observational research, which poses serious challenges to 
the determination of causality. Here, we review the studies 
testing the effect of bDMARDs on spinal radiographic 
progression, making use of the principles of causal 
inference. By exploring the assumptions of causality under 
counterfactual reasoning (exchangeability, positivity and 
consistency), we distinguish between studies that likely 
have reported confounded treatment effects and studies 
that, on the basis of their design, have more likely reported 
causal treatment effects. We conclude that bDMARDs 
might, indirectly, interfere with spinal radiographic 
progression in axSpA by their effect on inflammation. 
Innovations in imaging are expected, so that placebo- 
controlled trials can in the future become a reality. In the 
meantime, causal inference analysis using observational 
data may contribute to a better understanding of whether 
disease modification is possible in axSpA.
INTRODUCTION
Axial spondyloarthritis (axSpA) is character-
ised by inflammation and pathological new 
bone formation predominantly involving the 
spine and the sacroiliac joints (SIJ). Patients 
with axSpA and structural damage on pelvic 
radiographs, according to the modified New 
York criteria,1 are referred to as radiographic 
axSpA (r- axSpA) and the others as non- 
radiographic axSpA (nr- axSpA).
The C reactive protein (CRP) and the 
Ankylosing Spondylitis Disease Activity Score 
(ASDAS) are measures of disease activity 
that quantify systemic inflammation.2 Bone 
marrow oedema (BME) on MRI reflects 
local inflammation in vertebral corners and 
in the SIJ.3 Several studies have consistently 
shown that inflammation (ASDAS, CRP and 
BME) may lead to new bone formation.4–11 
Bone biopsy studies and animal models have 
provided the necessary biological framework, 
by showing that when BME subsides, it is 
replaced by a repair tissue with new bone- 
forming capability.12 13
Non- steroidal anti- inflammatory drugs 
(NSAIDs) constitute the first- line phar-
macological treatment in axSpA. Patients 
with axial involvement who do not respond 
to NSAIDs should be treated with biolog-
ical disease- modifying antirheumatic 
drugs (bDMARDs).14 Several randomised 
controlled trials (RCTs) have shown that 
tumour necrosis factor alpha inhibitors 
(TNFi) and interleukin 17 inhibitors (IL- 17i) 
are effective in suppressing inflammation and 
Key messages
 ► The evaluation of the structural effect of biological 
disease- modifying antirheumatic drugs (bDMARDs) 
in axial spondyloarthritis (axSpA) by a randomised 
controlled trial is currently unfeasible.
 ► Several observational studies addressed this endur-
ing and highly clinically relevant question.
 ► Observational research can yield causal treatment 
effects if key causal assumptions are met.
 ► Causal inference principles indicate that bDMARDs 
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alleviating symptoms, both in r- axSpA and nr- axSpA.15 
Since inflammation may trigger structural damage, ther-
apies that successfully suppress the former should, in 
theory, stop or at least retard the latter. However, after 
years of research, the structural effects of bDMARDs 
remain under debate.16
In some studies, bDMARDs did not appear to have 
structural effects, while in others, more positive results 
were found.17–19 We will explore this inconsistency by 
reviewing the literature under the principles of causal 
inference. We here use counterfactual reasoning as 
proposed by Rubin,20 Balke and Pearl21 and as recently 
revised by Gvozdenović et al.22 Treatment effects are 
considered causal, under the proviso of certain assump-
tions: exchangeability, positivity and consistency. We will start 
by defining causality under these assumptions. We will 
then use this definition as a benchmark to determine 
the likelihood of causality of the treatment effects from 
studies evaluating the structural effects of bDMARDs in 
axSpA. We conclude by anticipating the major advances 
expected in the field in the near future.
CAUSAL TREATMENT EFFECTS IN RCTS
Let us consider an individual patient with axSpA who 
starts a bDMARD. We quantify the patient’s spinal damage 
before the start of treatment and after a certain period 
of time and then record the change (factual outcome). 
Now, let us consider the same patient in a ‘counterfactual 
world’, in which no treatment was given. We measure the 
initial damage and again the change (counterfactual 
outcome). Because the patient is the same, it is obvious 
that any difference between the factual and the counter-
factual outcome must be caused by the treatment. Obvi-
ously, we will never observe the counterfactual outcome, 
so it is impossible to ascertain causality in an individual 
patient.
Let us now consider a population of patients with 
axSpA (figure 1A). In the hypothetical ‘world 1’, all 
patients receive a bDMARD. We follow them all and 
determine their mean progression (potential outcome 
1). We then hypothetically follow the same population 
of patients but give them a different drug (‘world 2’) and 
determine their mean progression (potential outcome 
2). Since the population is the same, it is obvious that 
any difference between outcomes 1 and 2 is caused by the 
treatment. Even though we cannot really observe the two 
potential outcomes, we can estimate their expected mean 
values, which is what we do in RCTs.
In an RCT, randomisation ensures that, at the group 
level, patients who actually get the bDMARD and those 
who get a comparator (usually placebo) have the same 
characteristics of their source population and, conse-
quently, are similar to each other. We say that treatment 
allocation is ignorable (it does not matter who gets what) 
and that the two groups are exchangeable (have the same 
characteristics). Had the patients who actually got the 
Figure 1 Causal effect versus association. Inspired by a figure from the following book: Hernán MA, Robins JM (2020). Causal 
inference: what if. Boca Raton: Chapman & Hall/CRC.50 The notation below each figure indicates either a mean difference or a 
risk ratio as measures of the treatment effect. For instance, in an observational study, we determine the difference between the 
mean value of mSASSS among patients on bDMARDs (Y|T=1) and the mean value of mSASSS among the controls (Y|T=0). We 
might also determine the risk of developing a new syndesmophyte among those on bDMARD (Y|T=1), relative (divided) to the 
risk of a new syndesmophyte in controls (Y|T=0). Unlike randomised controlled trials, the treatment effect is biased because 
each group is not representative of the entire source population and groups are therefore not exchangeable. axSpA, axial 
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bDMARD (factual world) hypothetically not got it (coun-
terfactual world), they would have the same potential 
outcome as those on the comparator. Measuring the 
outcome in two groups formed by randomisation is the 
same as measuring the outcome in all patients under 
hypothetical ‘world 1 and 2’ conditions.
In addition to exchangeability, causal claims also imply 
the positivity assumption, which is met when all patients, 
irrespective of their characteristics, have a probability 
greater than zero to be allocated to the treatment or to 
the comparator. Finally, both the intervention and the 
comparator need to be well defined, and their definition 
must not change during the time in which the treatment 
effect is being evaluated (consistency assumption).
The three causal assumptions are usually (but not 
always) met in RCTs, and that is why they are the gold 
standard in causal inference. Of note, modern trials in 
rheumatology, such as treat- to- target trials and (other) 
strategy trials will meet the criteria of exchangeability and 
positivity but fail the consistency criterion since the content 
of the treatment may vary over time.
Disease modification in axSpA: RCTs
The assessment of causal treatment effects implies the 
use of valid outcome measures. Spinal radiography has 
been the imaging modality of choice to measure struc-
tural damage in patients with axSpA. The modified Stoke 
Ankylosing Spondylitis Spinal Score (mSASSS) is the 
most often used score to measure spinal radiographic 
progression and performs better than any other score in 
terms of reliability, validity and sensitivity to change, both 
in patients with r- axSpA and nr- axSpA.23 24
Even though the mSASSS is the score with best sensi-
tivity to change, it still takes ≥2 years for a change to be 
observable, at the group level, in patients with r- axSpA.25 
Progression is even slower in early axSpA.26 Slow progres-
sion renders RCTs aiming at testing causal structural 
effects rather unfeasible. Patients in an RCT are all, by 
design, eligible to receive the treatment under study (eg, 
all have high levels of disease activity). As mentioned, 
bDMARDs reduce the signs and symptoms of the disease. 
It is therefore unethical to deprive patients from an effec-
tive therapy they would likely benefit from, for the time it 
takes to evaluate a potential structural effect. One alter-
native is to observe the effect of treatment as prescribed in 
clinical practice, a setting, however, in which the causality 
assumptions will less likely hold.
CAUSAL TREATMENT EFFECTS IN OBSERVATIONAL RESEARCH
Randomisation ensures that differences in outcomes 
between groups are fully explained by treatment. The 
same cannot be said if treatment prescription is not 
random but made by a clinician. Let us consider the 
population of patients with axSpA. In the factual world, 
only a fraction of patients, those who have failed—or 
are intolerant to—conventional treatment, are eligible 
to receive bDMARDs (figure 1B). That means treated 
patients usually have more severe disease than untreated 
patients. Treatment allocation is, therefore, not ignor-
able, and treated and untreated groups are not exchange-
able. This problem is often referred to as ‘confounding by 
indication’.
A confounder (‘C’) influences both the treatment 
decision (‘T’) and the outcome (‘Y’) and is not in the 
causal pathway between both (figure 2). For instance, 
patients with higher pretreatment levels of ASDAS (‘C’) 
are more likely to receive a bDMARD (‘T’) than those 
with lower levels. Also, higher ASDAS may lead to higher 
mSASSS (‘Y’). Thus, in a non- randomised experiment, 
bDMARDs may affect the mSASSS due to (1) a causal 
effect of the drug on mSASSS (‘front- door’ path: T→Y) 
or (2) a spurious effect of the drug on mSASSS through 
ASDAS (‘back- door’ path: T←C→Y). In an RCT, rando-
misation ‘closes’ all measured and unmeasured ‘back 
doors’ (figure 2A). In an observational study, the ‘back 
doors’ keep open, which may lead to spurious effects 
(figure 2B).
In addition to ASDAS (also CRP and BME), the pres-
ence of damage at baseline, male gender, longer disease 
duration and smoking all associate with radiographic 
progression.8 9 27 These characteristics are confounders 
if they also influence the decision to start a bDMARD. 
One possible solution is to ‘fix’ the values of confounders 
between treated and controls and estimate the so- called 
average marginal effect (AME) (figure 2C). Methods 
to estimate the AME, by ‘back- door’ adjustment, that 
is, methods used to take ‘confounding by indication’ 
into account, include matching, stratification, regres-
sion adjustment, propensity score (PS) adjustment and 
inverse probability of treatment weighting.
Under fixed values of all confounders, and assuming 
no unmeasured confounding, the treated and untreated 
are fully exchangeable. However, this alone does not suffice 
to guarantee causal treatment effects. In observational 
research, treatment groups are not necessarily consistently 
defined. Bias may also occur if patients under treatment 
who are included in studies, and are therefore compared 
with controls, have relevant prognostic dissimilarities 
with those who are not. If that happens, the positivity 
assumption is likely violated as patient’s characteristics 
are constraining treatment allocation (eg, if patients 
with worse prognostic factors have zero probability to be 
treated).
Disease modification in axSpA: observational research
Studies with equal exposure to treatment and without a 
comparator
After the completion of an RCT, patients on placebo 
usually switch to the active drug and, together with those 
on treatment from the start, are followed in open- label 
extensions (OLE), provided they meet certain inclusion 
criteria. The structural effect of bDMARDs in axSpA 
have, thus far, been evaluated in OLE with patients 
continuously exposed to TNFi for up to 10 years. All 
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also including patients with nr- axSpA. The number of 
patients in the original RCTs ranged from 84 to 325 and 
those in the corresponding OLEs (ie, with complete 
follow- up and imaging data) from 17 to 93.28–30 OLEs 
consistently report minimal change in the mSASSS. In 
one 4- year OLE, no meaningful change in mSASSS was 
observed in patients with nr- axSpA.30 In the same study, 
the change in mSASSS was higher in the first 2 years than 
in the last 2 years in patients with r- axSpA (0.8 vs 0.4), 
suggesting a late- onset structural benefit.
In studies without a comparator, which is the case 
in OLE, it is impossible to address the exchangeability 
assumption. The following counterfactual question 
remains unanswered: had the patients not received the 
bDMARD, would their average change in mSASSS be 
different than the observed change? In addition, the few 
patients that continue on treatment and are therefore 
included in the OLE are not necessarily representative of 
the larger population of patients eligible for bDMARDs 
from the corresponding RCTs. The positivity assumption 
is most likely violated, since patients with milder disease 
are, arguably, more likely to stay on treatment in the 
OLE (right censoring bias). On the contrary, the consis-
tency assumption is likely to hold, as all patients receive 
the same drug over the entire follow- up. Even if patients 
initially on placebo are included, this is usually for a well- 
defined and (very) short period of time.
Comparative studies with equal exposure to treatment
The large majority of studies evaluating the struc-
tural effect of bDMARDs included a comparator, and 
among these, most were done in a setting in which all 
patients had to be on bDMARD, or on the comparator, 
continuously over the entire study (time- fixed treat-
ment). Confounders, when considered, were evaluated 
at baseline before the start of treatment (time- fixed 
confounders), and the outcome was assessed at the end 
(time- fixed outcome).
Studies with time- fixed treatment compared patients 
with r- axSpA on bDMARD to either ineligible patients 
or patients in whom bDMARDs were not an option (eg, 
historical cohorts). Table 1 summarises the main find-
ings of studies reporting the mean change in mSASSS 
and table 2 the studies reporting binary definitions of 
progression (with some overlap). The effect size (Cohen’s 
d in table 2 and OR in table 3) was calculated (when not 
reported). In each table, the methods used for handling 
confounding are shown.
In three studies, patients on TNFi from OLEs were 
compared with patients not receiving TNFi from the 
Outcome in AS International Study (OASIS) historical 
cohort.31–33 As expected, patients on TNFi had worse 
prognostic factors (eg, higher levels of disease activity 
and damage) than patients from OASIS. Thus, patients 
on TNFi were compared with patients from OASIS who 
would have fulfilled the inclusion criteria of the OLE. The 
effect size was zero in the matched population (table 1) 
as well as in stratified and adjusted analyses. The absence 
of a structural effect was also reported in other studies 
comparing TNFi to no TNFi, as well as IL- 17i to NSAIDs, 
up to 2 years of follow- up.34–37
One study comparing 22 patients from an 8- year OLE 
with a historical cohort has shown slower progression 
Figure 2 Directed acyclic graphs (DAGs) representing (A) a causal effect in a randomised controlled trial, (B) an association 
in an observational study and (2C) an average marginal effect in an observational study. Black arrow, association of interest 
(‘front door’); red arrows, biasing paths (‘back doors’); crossed red arrows, closed biasing paths (eg, by randomisation in A and 
adjustment in C). Tb, treatment status at baseline (yes/no); Cb, a set of observed pretreatment confounders at baseline; Ub, a 
set of unobserved pretreatment confounders at baseline; Yf, outcome at follow- up. The notation below each DAG indicates 
either a mean difference or a risk ratio as measures of the treatment effect. The average marginal effect is the equivalent of a 
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with TNFi versus no TNFi after the fourth year of 
follow- up, adjusting for the mSASSS at baseline.38 In 
two cohort studies, patients on TNFi were compared 
with those not on TNFi after PS matching, with one 
showing a positive structural effect and the other no 
effect.39 40
Not all studies evaluating the effect of ‘time- fixed’ 
exposure to bDMARDs addressed confounding, and 
those that did considered only the effect of baseline 
variables (mostly damage). In studies that span for 
several years, it is arguable whether handling baseline 
confounding suffices for full exchangeability. Under null 
(or partial) exchangeability, it is reasonable to expect 
worse prognostic factors to dominate in the treated and 
therefore for underestimated structural effects. In addi-
tion, right censoring bias is likely, since patients had to 
keep the drug for several years to qualify for inclusion, 
thus violating the positivity assumption. Overestimation of 
the treatment effect is likely, if patients with better prog-
nosis are preferentially selected, since the comparison is 
made in a population most likely resembling the patients 
eligible to receive the control rather than the patients 
eligible for the treatment. Interpreting the direction 
of residual bias is difficult if neither assumption holds. 
Finally, the consistency assumption is likely not met when 
patients on bDMARD are compared with those not on 
bDMARD, as ‘no bDMARD’ is poorly defined and is likely 
to vary over time.
Comparative studies with variable exposure to treatment
In recent studies, patients were evaluated in regular inter-
vals. In order to be included, they only had to be followed 
during one period. For instance, a patient could only 
start a bDMARD in the second interval and then keep it 
until the end of the study (eg, six intervals in total, five 
on bDMARD). Another patient could have been treated 
since baseline but was lost to follow- up somewhere in the 
end of the first interval, thus ‘contributing’ with data to 
only one of six possible intervals. In this type of study, 
with unequal exposure to bDMARDs (‘time- varying’), 
the AME is the combined effect of treatment considering 
all available intervals, estimated with methods such as 
generalised estimating equations, that handle repeated 
observations per patient.
In studies with ‘time- varying’ treatment, treatment 
status is recorded at the start—and the outcome at the 
end—of each interval. Measures of disease activity (eg, 
ASDAS), damage (eg, mSASSS) and comedication (eg, 
NSAIDs), among other variables, are also recorded per 
interval. These features can be time- varying confounders, 
if they influence the prescription of bDMARDs at the 
start—and the outcome at the end—of each interval 
(figure 3A). ASDAS is also thought to mediate the 
structural effect of bDMARDs in axSpA. Importantly, 
a mediator, different to a confounder, resides in the 
causal pathway between the treatment and the outcome 
(figure 3B). Testing for mediation implies decomposing 
the total effect into (1) the direct effect of bDMARDs 






Handling of pretreatment 
confounders
Definition of 






2 INF 41 Adjust. (not clear which 
variables)
≥1 mSASSS 1.5 (0.4 to 6.5)*
No TNFi 41
van der 





2 INF 165 Match. (inclusion criteria), 
adjust. (mSASSS) and 
strat. (gender, age, CRP, 
BASDAI, BASFI, BASMI, 
PGA and HLA- B27)
≥1 mSASSS 0.9 (0.6 to 1.5)†
No TNFi 61
Haroon et al, 
201339
Cohort 1.5–9 TNFi 201 PS matching‡ ≥1 mSASSS/year 0.3 (0.1 to 0.8)‡
No TNFi 133
Kim et al, 
201640
Cohort 2–5 TNFi 269 PS matching§ ≥2 mSASSS 0.7 (0.3 to 1.6)§
No TNFi 341
*Calculated from observed data (p value of adjusted analysis not significant and no adjusted effect size reported).
†Calculated from observed data in the matched cohorts (adjusted and stratified analyses also not significant).
‡Adjusted OR after PS matching (n=142); baseline variables used to estimate the PS: gender, HLA- B27, BASDAI, ESR, mSASSS, NSAID 
index, disease duration, smoking pack- years and age of onset of symptoms.
§adjusted OR after PS matching (n=166 in each group); baseline variables used to estimate the PS: age, gender and CRP.
adjust, adjustment; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; 
BASMI, Bath Ankylosing Spondylitis Metrology Index; bDMARDs, biological disease- modifying antirheumatic drugs; CRP, C reactive protein; 
ESR, erythrocyte sedimentation rate; GESPIC, German Spondyloarthritis Inception Cohort; HLA, human leukocyte antigen; INF, infliximab; 
Match, matching; mSASSS, modified Stoke Ankylosing Spondylitis Spinal Score; NSAIDs, non- steroidal anti- inflammatory drugs; OASIS, 
Outcome in AS International Study; OLE, open- label extension; PGA, patient global assessment; PS, propensity score; strat, stratification; 
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on mSASSS adjusting for ASDAS (‘path a’) and (2) the 
indirect effect of bDMARDs through the reduction of 
ASDAS (path b), which in turn affects mSASSS (path c). 
Mediation occurs if the indirect effect drives part of the 
drug’s total effect.41 As illustrated in figure 3B, in theory, 
time- varying ASDAS can both confound and mediate the 
structural effects of bDMARDs.
The studies evaluating the effect of time- varying treat-
ment with bDMARDs on spinal radiographic progression 
are summarised in table 3. All studies tested only TNFi 
in patients with r- axSpA.39 42–46 Follow- up ranged from 
4 to 18 years; however, most patients had only contrib-
uted to few intervals. Both baseline and time- varying 
pretreatment confounders were considered, including 
measures of disease activity, damage and comedication. 
The total effect, adjusting for pretreatment confounders, 
was significant in all studies (table 3). Two studies tested 
whether ASDAS at the start of the interval was a time- 
varying mediator.44 46 Another study tested the mediating 
effect of the average value of CRP per interval.45 All three 
studies have shown that bDMARDs inhibit structural 
progression indirectly by lowering the levels of ASDAS 
(or CRP). In two of these studies, the direct effect of 
bDMARDs was not statistically significant,44 45 suggesting 
that the structural benefit was solely explained by the 
reduction of disease activity. In the third study, however, 
the direct effect of bDMARDs remained statistically 
significant after adjusting for ASDAS.46
Almost all studies reporting the time- varying structural 
effect of TNFi have handled time- varying confounding. 
Even though residual confounding is still a possibility, it 
can be argued that its likelihood is lower as compared with 
other types of studies discussed above. A claim of (full) 
exchangeability is therefore the only logical consequence. 
In addition, studies that allow a variable exposure to the 
treatment will minimise the risk of right censoring; both 
patients with a worse prognosis, who may be followed in 
fewer intervals, and those with a better prognosis, who 
may be followed in several intervals, can be included in 
the analysis. However, most studies had most patients 
followed for only a few intervals, which might render the 
positivity assumption less likely had a better balance been 
achieved. Finally, almost all studies compared treatment 
with TNFi with no TNFi, thus compromising the consis-
tency assumption.
SUMMARY AND FUTURE PERSPECTIVES
The effect of bDMARDs on spinal radiographic progres-
sion in patients with axSpA has been extensively studied 
over the past 15 years. Studies without a comparator 
suggest that bDMARDs may slow progression, but a claim 
of causality is implausible in such a setting. The exchange-
ability assumption is not even possible to assess, and posi-
tivity is unlikely due to right censoring bias. The likeli-
hood of causality increases in studies with a comparator. 
However, studies requiring all patients to stay on treat-
ment during the entire study are also susceptible to right 
censoring bias (worst patients drop out). In these studies, 
confounding was only considered at baseline limiting the 
likelihood of exchangeability. It is therefore difficult to 
interpret both the negative, short- term (≤2 years), studies 
and the inconsistent results from studies with longer 
follow- up. Studies with unequal (time- varying) exposure 
to treatment are the most likely to yield causal structural 
effects. Their design protects, to some extent, against 
‘right censoring’, thus making positivity more likely. In 
addition, these studies handle inherently time- varying 
confounders as such, thus increasing the chance of (full) 
exchangeability (table 4).
In all studies in the top of ‘causal hierarchy’, treatment 
with TNFi consistently reduced radiographic progression 
Figure 3 Directed acyclic graphs (DAGs) representing (A) a longitudinal study with time- varying confounding and (B) a 
longitudinal study with time- varying mediation. For the purpose of illustration, the DAGs are simplified (absent arrows) by 
making the following (unlikely to hold) assumptions: Yt+1 does not influence Tt+1; Yt+1 does not influence Yt+2; Ct does not 
influence Ct+1. Black arrows, associations of interest (‘front doors’); red arrows, biasing paths (‘back doors’); Tt, treatment 
status (yes/no) at the start of the first interval; Tt+1, treatment status at the start of the second interval; Ct, a set of pretreatment 
confounders at the start of the first interval; Ct+1, a set of pretreatment confounders at the start of the second interval; Yt+1, 
outcome at end of the first interval; Yt+2, outcome at the end of the second interval; Mt*, mediator measured after treatment 
assignment and before outcome assessment on the first interval; Mt+1*, mediator measured after treatment assignment and 
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as compared with no treatment. This effect was either 
partially or entirely mediated by their effect on inflam-
mation. A causal inflammation- mediated effect is in line 
with the evidence that inflammation drives structural 
progression and strongly argues in favour of a treat- to- 
target strategy in axSpA. In one study, a direct effect, that 
means through other (unknown) mechanisms, was also 
found. Although not implausible, the fluctuating nature 
of inflammation in axSpA can also explain this finding. 
‘No detectable inflammation’ (eg, no BME or ASDAS 
<1.3) is not necessarily the same as ‘no inflammation 
present’. Despite consistent results, studies with ‘time- 
varying’ treatment are not without limitations. Future 
studies addressing their limitations, as exposed here, will 
likely contribute to a better understanding of the struc-
tural effect of bDMARDs in axSpA.
Recent data suggest that the CT Syndesmophyte Score 
(CTSS) is more sensitive to change than the mSASSS.47 
Low- dose CT, and other imaging innovations, may render 
RCTs testing structural effects feasible in the future, by 
decreasing the time needed to observe a treatment effect. 
Of note, observational studies using CTSS as a measure 
of structural damage face similar challenges, as studies 
using the mSASSS, in identifying causal treatment effects. 
Trials comparing TNFi to IL- 17i are also expected but will 
only be informative if their structural effects really differ.16 
In the absence of an RCT, however, causal inference from 
observational research can still be informative.48 New 
causal analyses done with well- defined comparators will 
likely clarify the effect of TNFi on mSASSS in r- axSpA as 
well as in nr- axSpA and also for drugs other than TNFi.
Directed acyclic graphs (DAGs) are powerful instru-
ments in causal inference and will likely become more 
common in the rheumatological literature in the coming 
years. The model represented in a DAG (eg, figure 3) is 
causal, provided its underlying assumptions (arrows and 
nods) hold. This is why DAGs are also named structural 
causal models. In addition to ‘back- door’ adjustment, 
other methods such as ‘front- door’ adjustment with 
‘shielded mediators’ and instrumental variables can be 
used to handle confounding in structural causal models.49
Is disease modification possible in axSpA? The defin-
itive answer will likely be given in the next few years, 
by RCTs (when using a different structural damage 
assessment method, eg, with low- dose CT), but preceded 
by thorough theoretical causal analysis.
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